The Vasculitis Center at UPMC
Our comprehensive approach to treating vasculitis ensures a complete and thorough diagnosis and customized treatment plan to meet each patient’s individual needs. Our multidisciplinary center provides patients with convenient access to a team of board-certified specialists in rheumatology, nephrology, dermatology, ophthalmology, and pulmonary medicine.
The University of Pittsburgh partnership with UPMC is one of only nine academic institutions in the nation to earn the distinction of being named a “Vasculitis Center” by the Vasculitis Clinical Research Consortium, a member of the Rare Diseases Clinical Research Network that has been funded by the National Institutes of Health. Our team contributes to the growing field of vasculitis research and treatment by engaging in NIH-funded research, clinical trials, and education of health care providers and the general public.
If you would like more information regarding ongoing clinical studies at our Center, please contact Laurie K. Hope at 412-647-2638 or email@example.com.
Currently Recruiting Trials in Vasculitis
The Vasculitis Clinical Research Consortium: This is an organization funded by the National Institute of Health through the Rare Diseases Network. It is a coalition of medical research facilities that work together to conduct research on all types of vasculitis. Currently, there are eight studies currently recruiting patients. Please contact one of the study coordinators for more information.
ABROGATE: Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis (Wegener’s): This is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe GPA.
TAPIR: The Assessment of Prednisone in Remission Trial – Centers of Excellence Approach: TAPIR is a collaborative effort of the Vasculitis Clinical Research Consortium. It is sponsored by the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will include patients with a diagnosis of GPA with active disease in the last 12 months and documented remission status. Prednisone dose at the time of enrollment must be ≥ 6mg/day and ≤ 10mg/day.
Non-interventional registries: We are enrolling patients into non-interventional registries for the following types of vasculitis:
- Giant Cell Arteritis
- Takayasu’s Arteritis
- Polyarteritis Nodosa
- Granulomatosis with polyangiitis (Wegener’s)
- Microscopic Polyangiitis
- Churg-Strauss Syndrome
Division of Rheumatology and Clinical Immunology Offices
S700 Biomedical Science Tower
3500 Terrace Street
Pittsburgh, PA 15261
412-383-8000 | Email Us